[go: up one dir, main page]

AU2001244355A1 - Heterobiarylsulphonamides and their use as pde 7 inhibitors - Google Patents

Heterobiarylsulphonamides and their use as pde 7 inhibitors

Info

Publication number
AU2001244355A1
AU2001244355A1 AU2001244355A AU4435501A AU2001244355A1 AU 2001244355 A1 AU2001244355 A1 AU 2001244355A1 AU 2001244355 A AU2001244355 A AU 2001244355A AU 4435501 A AU4435501 A AU 4435501A AU 2001244355 A1 AU2001244355 A1 AU 2001244355A1
Authority
AU
Australia
Prior art keywords
heterobiarylsulphonamides
pde
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001244355A
Inventor
Hazel Joan Dyke
Frances Celia Anne Galvin
Alan Findlay Haughan
Christopher Lowe
Trevor Morgan
Catherine Louise Picken
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Darwin Discovery Ltd
Original Assignee
Darwin Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Darwin Discovery Ltd filed Critical Darwin Discovery Ltd
Publication of AU2001244355A1 publication Critical patent/AU2001244355A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001244355A 2000-03-31 2001-03-30 Heterobiarylsulphonamides and their use as pde 7 inhibitors Abandoned AU2001244355A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0007934 2000-03-31
GBGB0007934.3A GB0007934D0 (en) 2000-03-31 2000-03-31 Chemical compounds
PCT/GB2001/001479 WO2001074786A1 (en) 2000-03-31 2001-03-30 Heterobiarylsulphonamides and their use as pde 7 inhibitors

Publications (1)

Publication Number Publication Date
AU2001244355A1 true AU2001244355A1 (en) 2001-10-15

Family

ID=9888912

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001244355A Abandoned AU2001244355A1 (en) 2000-03-31 2001-03-30 Heterobiarylsulphonamides and their use as pde 7 inhibitors

Country Status (3)

Country Link
AU (1) AU2001244355A1 (en)
GB (1) GB0007934D0 (en)
WO (1) WO2001074786A1 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003011219A2 (en) * 2001-07-27 2003-02-13 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
BR0206161A (en) * 2001-10-19 2005-02-01 Ortho Mcneil Pharm Inc 2-phenyl benzimidazoles and imidazo- [4,5] -pyridines as cds1 / chk2 inhibitors and adjuvants for chemotherapy or radiation therapy in cancer treatment
US7378428B2 (en) * 2002-01-31 2008-05-27 Ono Pharmaceutical Co., Ltd. Nitrogen-containing bicyclic compounds and drugs containing the same as the active ingredient
DK1587821T6 (en) 2002-12-19 2025-05-26 Scripps Research Inst Compositions and methods for stabilizing trans-thyretin and inhibiting transthyretin misfolding
US7132440B2 (en) 2003-04-17 2006-11-07 Janssen Pharmaceutica, N.V. Substituted benzimidazoles and imidazo-[4,5]-pyridines
JP2006219373A (en) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Pyridinylpyrazolopyrimidinone derivatives having PDE7 inhibitory action
JP2006219374A (en) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Imidazotriazinone derivatives having PDE7 inhibitory action
US7592340B2 (en) 2003-12-04 2009-09-22 Vertex Pharmaceuticals Incorporated Quinoxalines useful as inhibitors of protein kinases
DE102004010194A1 (en) * 2004-03-02 2005-10-13 Aventis Pharma Deutschland Gmbh 4-Benzimidazol-2-yl-pyridazin-3-one derivatives, their preparation and use in medicaments
DE102004010207A1 (en) 2004-03-02 2005-09-15 Aventis Pharma S.A. New 4-benzimidazolyl-3(2H)-pyridazinone derivatives are kinase inhibitors, especially useful for treatment of cancer
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
AU2005245470A1 (en) 2004-05-20 2005-12-01 Foldrx Pharmaceuticals, Inc. 2-((hetero) aryl)-benzoxazole compounds and derivatives, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
EP1775298B1 (en) 2004-07-01 2013-03-20 Daiichi Sankyo Company, Limited Thienopyrazole derivative having pde7 inhibitory activity
US7538113B2 (en) 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7534796B2 (en) 2005-02-18 2009-05-19 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
US7582634B2 (en) 2005-02-18 2009-09-01 Wyeth 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7531542B2 (en) 2005-05-18 2009-05-12 Wyeth Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
US7582636B2 (en) 2005-05-26 2009-09-01 Wyeth Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
NZ565255A (en) * 2005-06-22 2010-04-30 Plexxikon Inc Pyrrolo[2,3-b] pyridine derivatives as protein kinase inhibitors
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
CN104758291B (en) 2007-03-27 2020-03-03 奥默罗斯公司 Use of PDE7 inhibitors for the treatment of movement disorders
MX2010000617A (en) 2007-07-17 2010-05-17 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor.
AU2010232670B2 (en) 2009-04-03 2015-07-09 F. Hoffmann-La Roche Ag Propane- I-sulfonic acid {3- [5- (4 -chloro-phenyl) -1H-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof
MA33975B1 (en) 2009-11-06 2013-02-01 Plexxikon Inc COMPOUNDS AND METHODS FOR MODULATING KINASES AND THEIR INDICATIONS FOR USE
BR112013006016A2 (en) 2010-09-15 2016-06-07 Hoffmann La Roche azabenzothiazole compounds, compositions and methods of use
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
KR20130124333A (en) 2010-11-08 2013-11-13 오메로스 코포레이션 Treatment of addiction and impulse-control disorders using pde7 inhibitors
HUE040136T2 (en) 2011-02-07 2019-02-28 Plexxikon Inc Compounds and Methods for Kinase Modulation and Their Indications
TWI558702B (en) 2011-02-21 2016-11-21 普雷辛肯公司 Solid forms of a pharmaceutically active substance
CN103781770B (en) 2011-09-16 2016-04-13 辉瑞公司 Transthyretin dissociates the solid form of inhibitor
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
WO2024038090A1 (en) 2022-08-18 2024-02-22 Mitodicure Gmbh Use of substituted benzoxazole and benzofuran compounds for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69723863T2 (en) * 1996-11-06 2004-04-15 Darwin Discovery Ltd., Slough CHINOLINE AND THEIR THERAPEUTIC USE
WO1999062905A1 (en) * 1998-06-03 1999-12-09 Almirall Prodesfarma, S.A. 8-phenylxanthine derivatives and their use as phosphodiesterase inhibitors

Also Published As

Publication number Publication date
WO2001074786A1 (en) 2001-10-11
GB0007934D0 (en) 2000-05-17

Similar Documents

Publication Publication Date Title
AU2001244355A1 (en) Heterobiarylsulphonamides and their use as pde 7 inhibitors
AU7392101A (en) 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors
AU2001249969A1 (en) Inha inhibitors and their use as antibacterials
AU2001240542A1 (en) Heterocyclic compounds and their use as parp inhibitors
AU2001265008A1 (en) Caspase inhibitors and uses thereof
AU2001270260A1 (en) 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
GB0025782D0 (en) Use of inhibitors
AU2002248269A1 (en) Use of p38 inhibitors for the treatment of inflammation-enhanced cough
AU2002225954A1 (en) Dipeptidylpeptidases and methods of use
AU2001249284A1 (en) L-arginine and phosphodiesterase (pde) inhibitor synergism
AU2002227985A1 (en) Pyrrolo (2.1-a) dihydroisoquinolines and their use as phosphodiesterase 10a inhibitors
AU2002230836A1 (en) Benzylamine derivatives and their use as thrombin inhibitors
AU2002213346A1 (en) Osteopontin-coated surfaces and methods of use
AU2002216650A1 (en) Triazine derivatives as lpaat-b inhibitors and uses thereof
PL361733A1 (en) Sulfamidothienopyrimidines and the use of the same as phosphodiesterase v inhibitors
AU2001293048A1 (en) Antiviral compositions and methods of use
AU2001276027A1 (en) Heteroaryl-beta-alanine derivatives as alpha 4 integrin inhibitors
AU2001232809A1 (en) Gyrase inhibitors and uses thereof
AU4501199A (en) 8-phenylxanthine derivatives and their use as phosphodiesterase inhibitors
AU2001266124A1 (en) 2-aminothiazoline derivatives and their use as no-synthase inhibitors
AU1039801A (en) Compounds and their use as cysteine protease inhibitors
AU4432001A (en) Trityl-type compounds and their use
AU2001268236A1 (en) Use of aicar and related compounds
AU2001261496A1 (en) Luxo-sigma54 interactions and methods of use
AU2001262928A1 (en) Pharmaceutical compositions and their use